"With praziquantel (PZQ) as the sole WHO-recommended treatment
for schistosomiasis, this theme systematically monitors
therapeutic outcomes in MDA communities, evaluating cure rates
and egg reduction rates according to standardized protocols."
The theme addresses in vitro and in vivo models detecting reduced
PZQ susceptibility in Schistosoma mansoni and
S. haematobium. Resistance markers — SmMRP1,
Smβ-tubulin polymorphisms, and genome-wide SNP profiles —
undergo validation across multiple Cameroon transmission sites.
Albendazole and mebendazole efficacy monitoring occurs against
Ascaris lumbricoides, Trichuris trichiura,
and hookworm species.
Key research activities
-
MDA efficacy trials
Controlled follow-up of treated cohorts measuring cure and
egg reduction rates across multiple sentinel sites.
-
Resistance marker screening
Molecular genotyping of parasite populations to detect SNPs
associated with reduced praziquantel susceptibility.
-
Anthelminthic monitoring
Annual ERR assessments for albendazole and mebendazole to
detect early signals of resistance emergence.
-
Alternative strategies
Evaluation of oxamniquine-PZQ combinations and novel drug
candidates as contingency options for confirmed PZQ resistance.